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Proteinuria is a characteristic ﬁnding in glomerular diseases and is closely associated with
renal outcomes. In addition, therapeutic interventions that reduce proteinuria improve
renal prognosis. Accumulating evidence has demonstrated that podocytes act as key
modulators of glomerular injury and proteinuria. The podocyte, or glomerular visceral
epithelial cell, is a highly specialized and differentiated cell that forms interdigitated foot
processes with neighboring podocytes, which are bridged together by an extracellular
structure known as the “slit diaphragm” (SD). The SD acts as a size- and charge-selective
barrier to plasma protein. Derangement of SD structure or loss of SD-associated protein
results in podocyte injury and proteinuria. During the past decades, several immune-
modulating agents have been used for the treatment of glomerular diseases and for the
reduction of proteinuria. Interestingly, recent studies have demonstrated that immuno-
suppressive agents can have a direct effect on the SD-associated proteins and stabilize
actin cytoskeleton in podocyte and have therefore introduced the concept of nonimmu-
nologic mechanism of renoprotection by immunomodulators. This review focuses on the
evidence that immuno-modulating agents directly target podocytes.
Copyright & 2015. The Korean Society of Nephrology. Published by Elsevier. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Minimal change disease (MCD) and focal segmental glomer-
ulosclerosis (FSGS) are one of the most common and important
causes of nephrotic syndrome (NS), accounting for 475% of NS
cases in children [1]. In adults, MCD and membranous nephro-
pathy (MN) are most frequent causes of idiopathic NS [2]. Heavy
proteinuria, hypoalbuminemia, edema, and related complications
such as thromboembolism, infection, and malnutrition are typi-
cal symptoms and signs of NS; in particular, a large amount of
protein in the urine often leads to progression to end-stage renal
disease. In addition, proteinuria is an indicator of treatment
response and important long-term prognostic marker in renal15. The Korean Society of Nep
.org/licenses/by-nc-nd/4.0/).
y and Hypertension, Departm
ity of Miami, 1600 North Wes
ornoni).disease progression. Increasing evidence suggests that podocyte
injury plays an important role in the development of proteinuria
and pathogenesis of various glomerular diseases, including MCD,
FSGS, and MN. Podocytes are terminally differentiated and cover
the urinary surface of glomerular basement membrane. Foot
process from one podocyte forms interdigitation with the foot
processes of adjacent podocytes to form the slit diaphragm (SD),
which functions as the ultimate ﬁlter with 4-  14-nm-sized
pores. Since the discovery of mutation of NPHS1 gene, which
codes for nephrin (an SD-associated protein), in patients with
Finnish-type congenital NS, mutations of several podocyte-
associated genes including CD2AP, TRPC6 [17], NPHS2, and NEPH1
were found to be associated with NS [3,4]. Podocytes andhrology. Published by Elsevier. This is an open access article under the
ent of Medicine, Peggy and Harold Katz Family Drug Discovery Center,
t 10th Avenue, Number 1140, Miami, FL 33136, USA.
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Figure 1. Schematic diagram showing nonimmunologic targets of immunosuppressive agents in podocytes. Glucocorticoids and levamisole
attenuate podocyte apoptosis and increase in RhoA activity and decrease in degradation of synaptopodin protein. Soluble urokinase receptor and
lipopolysaccharide activate B7-1 signaling and cathepsin L activity, whereas cyclosporine and abatacept inhibit synaptopodin degradation. Rituximab
enhances sphingomyelinase-like phosphodiesterase 3b expression and stabilizes synaptopodin.
GCR, glucocorticoids receptor; LPS, lipopolysaccharide; SMPDL-3b; sphingomyelinase-like phosphodiesterase 3b; suPAR, soluble urokinase receptor.
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target for therapeutic interventions in proteinuric kidney dis-
eases. Synaptopodin is an SD-associated protein, which main-
tains podocyte integrity. Dephosphorylation or ubiquitination (or
in some cases both) of synaptopodin induces derangement of
actin cytoskeleton, which results in foot process effacement [5].
Immunologic and metabolic stimuli including activation of
cytokine- and calcineurin-dependent mechanisms lead to degra-
dation of synaptopodin and podocyte injury [6].
Various immunosuppressive agents have been widely used to
treat glomerular diseases and the effects of these drugs were
thought to be solely immune mediated [7,8]. However, during
the past decade, advances in podocyte biology and pathogenesis
of proteinuric disease unveiled new molecular players respon-
sible for the development of proteinuria; in addition, unexpected
mechanisms of action of widely used immunosuppressive agents
that are independent of their traditional immunomodulatory
function have been discovered [9].
In this mini review, we describe the main targets of
immunosuppressive agents in podocytes and review their
mechanisms of action independent of immunological function.
Furthermore, we also suggest potential new targets for drug
development in podocytes. Because side effects develop in a
high proportion of patients with prolonged and high-dose
immunosuppressive treatment, it is important to understand
the optimal doses and target of immunosuppressive agents, as
low doses or speciﬁc targeted therapy may be more beneﬁcial
in patients with proteinuric kidney diseases. Fig. 1 shows a
schematic diagram for nonimmunologic targets of immuno-
suppressive agents in podocytes. Potential targets of immuno-
suppressive agents in podocytes are given in Table 1.Evidence of immunologic mechanisms in idiopathic NS
Shalhoub [10] hypothesized that MCD is associated with
lymphocyte-derived permeability factor and increasing evidence
suggests that cell-mediated immune systems are activated inMCD. Development of MCD is coincidental in Hodgkin’s lym-
phoma, which is a T-cell disorder [11]. Incidence of atopy, which is
also associated with cell-mediated hypersensitivity, is higher in
patients with MCD [12]. Idiopathic NS responds to immuno-
suppressive agents such as corticosteroid and cyclosporine to
suppress cell-mediated immunity. In addition, immunologic
mechanisms are supported based on several clinical observations
that relapse of MCD is experienced after viral or bacterial infec-
tions, inhaling allergens, and vaccination. Some studies reported
that T cells are clonally expanded and cytokines derived from
activated T and B cells are elevated in patients with idiopathic NS
[13,14]. van den Berg and Weening [15] also demonstrated that
interleukin (IL)-10 and IL-13 as cytokines produced by T lympho-
cytes are elevated in patients with MCD. IL-10 and IL-13 were
normalized after remission of NS, whereas the protein concentra-
tions and messenger RNA (mRNA) levels were upregulated again
following NS relapse [15]. In addition, autoantibodies to PLA2R1
bind to epitopes on speciﬁc domains of PLA2R1 expressed on the
podocyte surface and this phenomenon is demonstrated as a key
pathogenetic mechanism in idiopathic MN [16,67]. However,
cyclosporine therapy reduced proteinuria in human and experi-
mental Alport’s syndrome models and in patients with NPHS2
mutation and nonimmunological and genetic glomerular diseases.
Although cyclosporine decreased proteinuria in patients with MN,
repeat kidney biopsy results showed many large electron-dense
immune deposits [18–21]. Recent studies also demonstrated that
circulating permeability factors are related to the development of
NS [22]. These observations suggest that the action of these agents
might be beyond immune mechanisms.Nonimmunologic targets of immunosuppressive agents
in podocytes
Glucocorticoids
Glucocorticoids has been widely used for many years and is
the standard ﬁrst-line drug for patients with MCD and FSGS;
Table 1. Potential targets of immunosuppressive agents in podocytes
Immunosuppressive
agent
Mode of action Action in podocytes
Glucocorticoids Blocks action of interleukin-2 Increases Bcl-2 & decreases p53 & CDK p21
Reduces T-cell proliferation Attenuates podocyte apoptosis & prolongs podocyte survival
Suppresses clonal expansion of B-cell & antibody
production
Increases RhoA activity & stabilizes actin ﬁlaments
Levamisole Controls balance between type 1 & type 2 immune
response
Activates glucocorticoids receptor signaling
Calcineurin inhibitors Inhibits NFAT signaling in T cells Prevents synaptopodin degradation by cathepsin L
Suppresses T-cell function Stabilizes phosphorylated synaptopodin & actin-cytoskeleton
derangement
Reduces cytokine production from T cells Downregulates TRPC6 expression
Rituximab Monoclonal antibody to CD20 Recovers SMPDL-3b mRNA & protein expression
Growth inhibition of B cells
Abatacept Inhibits costimulatory signaling (CD80–CD86) Blocks B7-1 signaling
Regulates T- & B-cell-mediated immunity Restores β1 integrin activation
S1P agonist Sequesters lymphocytes Downregulates VEGF & TNF-α
Inhibits T-cell chemotaxis & proliferation Upregulates nephrin & podocin
mTOR inhibitor Cell cycle arrest at the G1 phase Enhances autophagy & maintains podocyte integrity
Impair T-cell proliferation
CDK, cyclin-dependent kinase; mRNA, messenger RNA; mTOR, mammalian target of rapamycin; NFAT, nuclear factor of activated T cell; S1P,
sphingosine-1-phosphate; SMPDL-3b, sphingomyelinase-like phosphodiesterase 3b; TNF, tumor necrosis factor; TRPC6, transient receptor potential
channel 6; VEGF, vascular endothelial growth factor.
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kidney in this group of patients remains unclear. Glucocorti-
coid suppresses cell-mediated immunity by blocking the
action of cytokines including IL-2, and subsequently reducing
T-cell proliferation. These effects of glucocorticoids also dimin-
ish humoral immunity by suppressing B-cell clonal expansion
and antibody production. However, puromycin aminonucleo-
side (PAN)-induced NS, which is a well-described model of
MCD and FSGS, has no evidence of immunologic mechanisms,
and glucocorticoids ameliorates proteinuria in PAN-induced
nephrosis. In addition, glucocorticoids exerts its action by
binding to the intracellular glucocorticoids receptors (GCRs),
which are present in glomerular cells including podocytes.
Glucocorticoids attenuates podocyte apoptosis in PAN-induced
podocyte injury by restoration of Bcl-2 and reduction of p53 in
PAN-treated podocytes [23,24]. Glucocorticoids also prevents
PAN-induced translocation of apoptosis-inducing factor.
Another study showed that glucocorticoids upregulated
nephrin and downregulated vascular endothelial factor in
podocytes. In addition, glucocorticoids downregulated cyclin
kinase inhibitor p21 and IL-6 expression and augmented
podocyte survival [25]. Glucocorticoids in podocytes not only
reduces apoptosis, but also enhances recovery by stabilizing
actin ﬁlaments and maintaining podocyte survival. This pro-
tective effect against actin-cytoskeleton depolymerization in
podocytes is glucocorticoids speciﬁc and could be mediated by
increase in the activity of Rho-A (a small guanosine tripho-
sphatase protein), which plays an important role in stress ﬁber
stabilization [26]. More recently, the possibility that ACTH may
directly target podocytes via melanocortin receptor 1 has also
been studied [66].
Levamisole
Levamisole was a synthetic imidazole derivative used for its
anthelmintic effects. Because adverse effects including agra-
nulocytosis have been reported, levamisole is no longer used
to treat parasitic infections. However, this drug has animmune-modulating action and has been used in the treat-
ment of some cancers such as colon cancer and melanoma
[27,28]. Levamisole, which modulates type 1 and type
2 immune responses through enhancing IL-18 activity, has
also been used for the treatment of NS in children [8,29]. A
recent study [30] also reported that levamisole is able to
induce expression of GCR activities and to activate GCR
signaling in human podocytes, suggesting that levamisole
can also directly affect the targets in podocytes.
Calcineurin inhibitors
Calcineurin inhibitors including cyclosporine A (CsA) are
widely used in patients who received organ transplantation. It
is also effective for patients with various glomerulopathies
including refractory NS, for both the steroid-dependent relap-
sing (steroid-dependent nephrotic syndrome) and the steroid-
resistant (steroid-resistant nephrotic syndrome) types [31].
CsA is an option for patients who have not responded to
conventional steroid treatment and also may now serve as a
ﬁrst-line immunosuppressant for treating childrenwith refrac-
tory NS. Cyclosporine inhibits nuclear factor of activated T-cell
signaling, which results in inhibition of calcineurin activity in
T-cells [32]. CsA also reduced cytokine production and effec-
tively suppressed the T-cell function. The mode of action of
cyclosporine in reducing proteinuria is not merely linked to its
immunosuppressive effects, as a reduction of proteinuria
following cyclosporine therapy is also observed in nonimmu-
nologic glomerular injury such as Alport’s syndrome and PAN-
induced nephrosis. In addition, low doses of CsA, which
showed ineffective immunosuppressive action, also reduced
proteinuria in MCD and MN. A previous report by Faul et al
[33] revealed that podocyte is a direct target of CsA.
Calcineurin-mediated dephosphorylation of synaptopodin
leads to degradation by cytosolic cathepsin L, which subse-
quently results in destabilization of podocyte actin cytoskele-
ton and changes in motile phenotype of podocytes. CsA
induces synaptopodin to bind to the 14-3-3 site and stabilizes
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lated synaptopodin becomes refractory to degradation by
cathepsin L. In this mechanism, CsA stabilizes the stress ﬁber
of podocyte and prolongs podocyte survival. This suggests that
even lower doses of CsA would be effective in reducing
proteinuria. Transient receptor potential channel 6 (TRPC6)
in podocytes enhances calcium inﬂux and increases their
motility. TRPC6 overexpression has been observed in patients
with familial-type FSGS as well as acquired forms of NS
[17,34,35]. CsA was reported to downregulate TRPC6 expres-
sion in an animal model of FSGS [36]. CsA can also induce
vasoconstriction in the afferent arterioles in the kidneys,
causing changes in surface charge and permselectivity of the
glomerular ﬁltration barrier [37].
Rituximab
Rituximab is a chimeric monoclonal antibody that binds to the
B-cell surface antigen CD20 and depletes B-cell lineage [38].
Rituximab also binds to acid sphingomyelinase-like phospho-
diesterase 3b (SMPDL-3b) protein, which induces acid sphingo-
myelinase activity and mediates growth inhibition on B cells [39].
This drug has been used for the treatment of B-cell-proliferating
hematologic malignancies and antibody-associated acute rejec-
tion in kidney transplantation [38]. Because complete remission
of NS unexpectedly occurs in patients with post-transplant
recurrent FSGS treated with rituximab, this monoclonal antibody
has been a promising candidate drug for treating recurrent or
refractory FSGS [40]. Rituximab was occasionally effective to treat
some cases of post-transplant recurrent FSGS and refractory FSGS
in uncontrolled studies. However, little is known about B-cell-
associated mechanisms in FSGS [41,42]. A recent study revealed
that human glomeruli including podocytes expressed neither
CD20 mRNA nor protein, and rituximab restored actin-
cytoskeletal derangement through B-cell-independent mechan-
isms. A previous study demonstrated decreased glomerular
SMPDL-3b expression in patients with recurrent FSGS after
kidney transplantation and reduced acid sphingomyelinase activ-
ity in podocytes treated with sera from these patients [43]. A
recent study also demonstrated that glomerular SMPDL-3b
mRNA expression was decreased in FSGS patients. In podocytes
treated with sera of high-risk FSGS patients, podocyte apoptosis
and loss of stress ﬁber were observed [44]. Sera of patients with
recurrent FSGS after kidney transplantation induce actin-
cytoskeleton derangement. The restoration of SMPDL-3b expres-
sion in podocytes by rituximab prevented the disruption of stress
ﬁber and podocyte apoptosis. An ongoing randomized clinical
trial conducted at the University of Miami, Miami, FL, USA, will
help determine whether rituximab can prevent FSGS recurrence
after kidney transplant and to determine whether such protec-
tion is associated with a modulation of SMPDL-3b expression in
podocytes.
Abatacept B7-1-blocking agents
B7-1 (CD80) and B7-2 (CD86), known as costimulatory
molecules, are transmembrane proteins usually expressed on
the surface of antigen-presenting cells (macrophages and B
cells) and bound to CD28 constitutively expressed on T cells
[45]. CD80 and CD86 provide costimulatory signals to regulate
T-cell-mediated immunity by the production of various ILs,
especially IL-2 and IL-6. Costimulatory modulators have been
developed and highlighted as promising agents formaintaining immunosuppression in organ transplantation
and for treatment of rheumatoid arthritis [46,47]. Meanwhile,
B7-1 and B7-2 are also expressed in glomeruli. In particular,
B7-1 is abundantly expressed in podocyte and its expression is
enhanced in experimental primary glomerular disease. In
addition, urinary B7-1 concentrations in patients with MCD
were increased. B7-1 in urine returned to the normal range
during remission but re-elevated during the relapse in these
patients. Reiser et al [48] also clearly demonstrated the role of
B7-1 in derangements of actin cytoskeleton in podocytes. They
showed that lipopolysaccharide (LPS), which is an endogenous
inducer of B7-1 through Toll-like receptor-4 signaling, upre-
gulated actin-cytoskeletal reorganization and induced foot
process effacement and proteinuria, but knocking-down of
B7-1 ameliorated LPS-induced cytoskeletal changes in podo-
cytes. These changes are also observed in severe combined
immunodeﬁciency mice, which suggested that the action of
B7-1 in podocyte injury is associated with T- and B-cell-
independent mechanisms. Galiximab, an anti-CD80 monoclo-
nal antibody, has been used for treatment of hematologic
malignancy such as relapsed non-Hodgkin’s lymphoma
[49,50]. Recently, Yu and co-workers [51] demonstrated that
B7-1-blocking agents (abatacept) may become considerable
therapeutic agents in patients with FSGS. B7-1-positive podo-
cytes showed near-complete loss of β1 integrin activation and
increase in motility. However, abatacept restored β1 integrin
activation and reversed podocyte motility. In addition, abata-
cept treatment was associated with partial or complete remis-
sion of proteinuria in a very small series of patients with FSGS
or recurrent FSGS after renal transplantation. Should these
data be conﬁrmed in prospective randomized clinical trials, it
is possible to envision the development of personalized
therapeutic decisions. In particular, patients with proteinuria
would be classiﬁed as either B7-1-positive or B7-1-negative
kidney disease in their renal biopsy samples. B7-1-blocking
agents might be potential therapeutic agents in patients with
FSGS, and therefore, additional clinical studies are needed in
this regard.
Sphingosine-1-phosphate agonist: FTY720
FTY720, which is an immunosuppressive B7-1 positive
agent approved for treatment of multiple sclerosis, might be
a potential candidate for the treatment of podocyte injury.
Sphingosine-1-phosphate (S1P) is a biologically active sphin-
gomyelin metabolite and is phosphorylated by sphingosine
kinase-1. S1P exerts its action by binding to ﬁve structurally
related G-protein-coupled receptors (S1P1–S1P5 receptors)
[52]. Because S1P sequesters lymphocytes and inhibits T-cell
chemotaxis and T-cell proliferation [53], the S1P agonist
FTY720 is proposed to treat transplant rejection and autoim-
mune disease such as multiple sclerosis [54,55]. Besides,
FTY720 has a protective effect on ischemia-reperfusion animal
models and improved diabetic kidney injury without altera-
tions of T and B cells [56,57]. In addition, a selective S1P
agonist, SEW2871, abolished high glucose (HG)-induced vas-
cular endothelial growth factor and tumor necrosis factor-α
upregulation in podocytes, and also improved proteinuria
through restoration of podocyte-speciﬁc molecules such as
nephrin and podocin in streptozotocin-induced diabetic
nephropathy. These data indicate that the S1P agonist directly
affected podocytes and also might be a therapeutic candidate
in diverse podocytopathic diseases.
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Rapamycin, a mammalian target of rapamycin (mTOR) inhi-
bitor, inhibits mTOR activity, eventually leading to cell cycle
arrest at the G1 phase [58]. mTOR inhibitors impair T-cell
proliferation and are used for immunosuppression after renal
transplantation [59]. mTOR, including mTORC1 and mTORC2, is
abundant in podocyte and plays a role in development of
podocyte damage [60]. Rheb activates mTOR signaling, but the
activities of TSC1 and TSC2 complexes decrease in mTOR
activation. TSC1/TSC2 is inhibited by phosphoinositide 3-kinase
(PI3K) and is upregulated by 50-adenosine monophosphate-
activated protein kinase (AMPK) [61]. Epidermal growth factor
activates the protein kinase B–PI3K pathway and abundant
nutrients including HG and amino acid inhibit AMPK activation
[62]. HG-induced epidermal growth factor signaling activation
and AMPK inactivation propagate mTOR signaling, subsequently
suppressing autophagy in early diabetic nephropathy; by
contrast, mTOR inhibition enhances autophagy and prevents
diabetic nephropathy [63]. However, chronic mTOR inhibition
also induced podocyte injury in diabetic models and in kidney
transplant recipients [64,65]. Taken together, a balance of
mTOR signaling might be important for maintenance of podo-
cyte integrity and development of podocyte damage [9]. A more
speciﬁc Understanding of a mTOR pathway in podocyte might
be applicable to therapeutic agents in glomerular diseases.Conclusion
The effect of immunosuppressive agents in glomerular
diseases is attributed to immune-dependent mechanisms.
However, recent studies demonstrated that the antiproteinuric
effect of these agents might be associated not only with their
immunosuppressive action, but also via a direct effect on
podocytes. Elucidation of direct target of the currently avail-
able immunosuppressive agents in podocytes might be helpful
to search for new drugs without undesirable adverse reactions
associated with immunosuppression.Conﬂict of interest
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